ClinVar Miner

Submissions for variant NM_000535.7(PMS2):c.88C>T (p.Gln30Ter) (rs141577476)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000131992 SCV000187050 pathogenic Hereditary cancer-predisposing syndrome 2018-01-08 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Alterations resulting in premature truncation (e.g.reading frame shift, nonsense)
Color RCV000131992 SCV000905476 pathogenic Hereditary cancer-predisposing syndrome 2018-03-22 criteria provided, single submitter clinical testing
GeneDx RCV000521392 SCV000621341 pathogenic not provided 2017-10-06 criteria provided, single submitter clinical testing The Q30X variant in the PMS2 gene has been reported previously in individuals with endometrial and/or ovarian cancer (Goodenberger et al., 2016). At least one tumor showed absence of PMS2 via mismatch repair immunohistochemistry (Goodenberger et al., 2016). The substitution creates a nonsense variant, which changes a Glutamine to a premature stop codon (CAG>TAG), and is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. The Q30X variant is not observed in large population cohorts (Lek et al., 2016). Loss-of-function variants are known to be pathogenic in this gene associated with Lynch syndrome. Therefore, based on the ACMG recommendations, Q30X is interpreted as an expected pathogenic sequence change.
Invitae RCV000684779 SCV000552069 pathogenic Hereditary nonpolyposis colon cancer 2018-11-06 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Gln30*) in the PMS2 gene. It is expected to result in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). This variant has been observed in the literature in an individual with endometrial and ovarian cancer (PMID: 25856668). ClinVar contains an entry for this variant (Variation ID: 142650). Loss-of-function variants in PMS2 are known to be pathogenic (PMID: 21376568, 24362816). For these reasons, this variant has been classified as Pathogenic.
Laboratory for Molecular Medicine,Partners HealthCare Personalized Medicine RCV000475400 SCV000712559 pathogenic Lynch syndrome 2016-11-16 criteria provided, single submitter clinical testing The p.Gln30X variant in PMS2 has been reported in 2 individuals with Lynch syndr ome-associated cancers (Goodenberger 2015), and was absent from large population studies. This nonsense variant leads to a premature termination codon at positi on 30, which is predicted to lead to a truncated or absent protein. Heterozygous loss of function of the PMS2 gene is an established disease mechanism in Lynch Syndrome. In summary, this variant meets criteria to be classified as pathogenic for Lynch Syndrome in an autosomal dominant manner.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.